DK0667787T3 - Gruppe B-streptococcus type II- og type V-polysaccharid-protein-konjugat-vacciner - Google Patents

Gruppe B-streptococcus type II- og type V-polysaccharid-protein-konjugat-vacciner

Info

Publication number
DK0667787T3
DK0667787T3 DK93922357T DK93922357T DK0667787T3 DK 0667787 T3 DK0667787 T3 DK 0667787T3 DK 93922357 T DK93922357 T DK 93922357T DK 93922357 T DK93922357 T DK 93922357T DK 0667787 T3 DK0667787 T3 DK 0667787T3
Authority
DK
Denmark
Prior art keywords
type
cps
streptococcus
group
protein conjugate
Prior art date
Application number
DK93922357T
Other languages
Danish (da)
English (en)
Inventor
Harold J Jennings
Dennis L Kasper
Original Assignee
Ca Nat Research Council
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26823688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0667787(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ca Nat Research Council, Brigham & Womens Hospital filed Critical Ca Nat Research Council
Priority claimed from PCT/US1993/009056 external-priority patent/WO1994006467A1/en
Application granted granted Critical
Publication of DK0667787T3 publication Critical patent/DK0667787T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/813—Carrier is a saccharide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK93922357T 1992-09-24 1993-09-24 Gruppe B-streptococcus type II- og type V-polysaccharid-protein-konjugat-vacciner DK0667787T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94997092A 1992-09-24 1992-09-24
US12555693A 1993-09-23 1993-09-23
PCT/US1993/009056 WO1994006467A1 (en) 1992-09-24 1993-09-24 Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines

Publications (1)

Publication Number Publication Date
DK0667787T3 true DK0667787T3 (da) 2001-10-29

Family

ID=26823688

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93922357T DK0667787T3 (da) 1992-09-24 1993-09-24 Gruppe B-streptococcus type II- og type V-polysaccharid-protein-konjugat-vacciner

Country Status (16)

Country Link
US (2) US5795580A (ko)
EP (1) EP0667787B1 (ko)
JP (3) JP4163251B2 (ko)
KR (1) KR100293017B1 (ko)
AT (1) ATE203167T1 (ko)
AU (1) AU690525B2 (ko)
CA (1) CA2145397C (ko)
DE (1) DE69330464T2 (ko)
DK (1) DK0667787T3 (ko)
ES (1) ES2160601T3 (ko)
FI (1) FI110993B (ko)
GR (1) GR3036928T3 (ko)
IL (1) IL107103A (ko)
NO (2) NO319569B1 (ko)
NZ (2) NZ299249A (ko)
PT (1) PT667787E (ko)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0843372B1 (en) * 1996-11-18 2003-03-12 Japan Storage Battery Company Limited Positive electrode for lithium battery and lithium battery
CA2320470A1 (en) * 1998-02-05 1999-08-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine Simplified method for removing free protein during preparation of protein-polysaccharide conjugates and vaccines using restricted-access media
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
AU2001281168A1 (en) 2000-08-08 2002-02-18 St. Jude Children's Research Hospital Group b streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof
SV2003000753A (es) * 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
US20030185858A1 (en) * 2001-08-15 2003-10-02 Birkett Ashley J. Immunogenic HBc chimer particles stabilized with an N-terminal cysteine
WO2003015815A1 (en) * 2001-08-21 2003-02-27 The Brigham And Women's Hospital, Inc. Improved conjugate vaccines
WO2004011027A1 (en) * 2002-07-30 2004-02-05 Baxter International Inc. Chimeric multivalent polysaccharide conjugate vaccines
WO2004089407A2 (en) * 2003-03-31 2004-10-21 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
JP4764820B2 (ja) * 2003-06-23 2011-09-07 バクスター・インターナショナル・インコーポレイテッド ワクチン用担体タンパク質
JP2008518953A (ja) * 2004-11-01 2008-06-05 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 連鎖球菌修飾多糖類およびそれらの使用法
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
US8206726B2 (en) * 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
GB201101665D0 (en) * 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2013009945A1 (en) 2011-07-12 2013-01-17 The Brigham And Women's Hospital, Inc. Lipid-containing psa compositions, methods of isolation and methods of use thereof
CN104582718B (zh) 2012-10-03 2017-10-24 诺华股份有限公司 免疫原性组合物
EP3292146A1 (en) * 2015-05-04 2018-03-14 Pfizer Inc Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
WO2017031431A1 (en) 2015-08-19 2017-02-23 President And Fellows Of Harvard College Lipidated psa compositions and methods
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use
US20220211859A1 (en) * 2019-05-10 2022-07-07 Glaxosmithkline Biologicals Sa Conjugate production

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324887A (en) * 1978-08-16 1982-04-13 President And Fellows Of Harvard College Type II group B Streptococci polysaccharide
US4207414A (en) * 1978-08-16 1980-06-10 President And Fellows Of Harvard College Polysaccharide antigens
IE51174B1 (en) * 1980-04-14 1986-10-29 Merck & Co Inc Group b streptococcal capsular polysaccharides
US4438261A (en) * 1980-05-19 1984-03-20 Riker Laboratories, Inc. Anticoagulant substance
US4356263A (en) * 1980-06-09 1982-10-26 President And Fellows Of Harvard College Method of making a polysaccharide vaccine
US4367223A (en) * 1980-06-09 1983-01-04 President And Fellows Of Harvard College Vaccine against Group B streptococci
US4367222A (en) * 1980-06-09 1983-01-04 President And Fellows Of Harvard College Immune globulin specific to Group B streptococci
US4367221A (en) * 1980-06-09 1983-01-04 President And Fellows Of Harvard College Immunization against Group B streptococci
US4284537A (en) * 1980-07-03 1981-08-18 The United States Of America As Represented By The Department Of Health And Human Services Conjugate of streptococcal M protein peptide vaccine
US4425330A (en) * 1981-05-20 1984-01-10 Cornell Research Foundation, Inc. Bovine mastitis vaccine and method for detecting efficacy thereof
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4757134A (en) * 1982-12-02 1988-07-12 The Rockefeller University IgA binding protein
ATE70308T1 (de) * 1984-09-12 1991-12-15 Chiron Corp Hybridpartikel-immunogene.
FR2581877B1 (fr) * 1985-05-14 1987-12-18 Louvain Universite Catholique Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries
US5302386A (en) * 1986-04-16 1994-04-12 Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines and methods of manufacture
EP0302887B1 (en) * 1986-04-16 1994-06-22 The Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines, and methods of manufacture
NZ225372A (en) * 1987-07-17 1991-04-26 Xoma Corp Immunotoxin composition comprising purified ricin-a-chain species
IL95578A (en) * 1989-09-15 1998-08-16 Gen Hospital Corp A vaccine made from polysaccharide and protein
AU641715B2 (en) * 1989-12-14 1993-09-30 National Research Council Of Canada Improved meningococcal polysaccharide conjugate vaccine
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.

Also Published As

Publication number Publication date
FI951412A (fi) 1995-05-24
ATE203167T1 (de) 2001-08-15
NO319569B1 (no) 2005-08-29
EP0667787A1 (en) 1995-08-23
KR100293017B1 (ko) 2001-09-17
CA2145397A1 (en) 1994-03-31
NO951109L (no) 1995-05-22
FI110993B (fi) 2003-05-15
NO951109D0 (no) 1995-03-23
JPH08501563A (ja) 1996-02-20
JP4163251B2 (ja) 2008-10-08
ES2160601T3 (es) 2001-11-16
US5795580A (en) 1998-08-18
JP2005306884A (ja) 2005-11-04
NO951152D0 (no) 1995-03-24
DE69330464T2 (de) 2001-11-08
FI951412A0 (fi) 1995-03-24
AU690525B2 (en) 1998-04-30
JP4308174B2 (ja) 2009-08-05
EP0667787B1 (en) 2001-07-18
CA2145397C (en) 2007-10-30
KR950703361A (ko) 1995-09-20
AU5137893A (en) 1994-04-12
DE69330464D1 (en) 2001-08-23
NZ248766A (en) 1996-11-26
PT667787E (pt) 2001-10-31
IL107103A (en) 2001-03-19
US5993825A (en) 1999-11-30
NZ299249A (en) 2000-08-25
GR3036928T3 (en) 2002-01-31
IL107103A0 (en) 1994-08-26
JP2009132727A (ja) 2009-06-18

Similar Documents

Publication Publication Date Title
DK0667787T3 (da) Gruppe B-streptococcus type II- og type V-polysaccharid-protein-konjugat-vacciner
ES8704350A1 (es) Procedimiento para la preparacion de un conjugado bacteriano
CA1276109C (en) Immunogenic conjugates
US5425946A (en) Vaccines against group C Neisseria meningitidis
NO913518L (no) Vaksiner for ikke typebestembar haemophilus influenzae.
IE840197L (en) Polysaccharide protein conjugate vaccine
US5192540A (en) Haemophilus influenzae type b oxidized polysaccharide-outer membrane protein conjugate vaccine
CA2171942A1 (en) Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
LU91609I2 (fr) Sérotype pneumococcique polysaccharidique 1,4,5,6B,7F,9V,14 et 23F conjugé aux protéines D (dérivé du non-typable Haemophilus influenzae); Sérotype pneumococcique polysaccaridique 18C conjugé au transporteur anatoxine tétanique protéines; Sérotype pneumococcique polysaccharidique 19F conjugé au transporteur anatoxine diphtérique protéines (SYNFLORIX - Vaccin pneumococcique polysaccharidique conjugé (adsorbé)
PT81338A (en) Antigens particularly envelope antigens of the virus of lymphadenopathies and of the acquired immuno-depressive syndrome and virus process for producing virus envelope antigens in the preparation of immunogenic compositions or for the diagnosis of the presence of antibodies against this virus
IL118603A (en) Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
IL115047A0 (en) Pneumococcal polysaccharide - recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections.
SI20008B (en) Improved meningococcal polysaccharide conjugate vaccine
DE3477883D1 (en) Antigenic materials
Fattom et al. Synthesis and physicochemical and immunological characterization of pneumococcus type 12F polysaccharide-diphtheria toxoid conjugates
EP0338265B1 (en) Haemophilus influenzae type B polysaccharide-outer membrane protein conjugate vaccine
US6165468A (en) Antigenic carbohydrate linked to an immunogenic carrier
UA27754C2 (uk) Комбінована педіатрична вакцина, спосіб одночасної комбінованої вакцинації
KR910011897A (ko) 말라리아 백신
WO1993014206A3 (en) Synthetic peptides for a rubella vaccine
Lüscher et al. Induction of immunological tolerance to the penicilloyl antigenic determinant—iv. The effect of BPO-oligolysines and cholestanol-bearing BPO-oligolysines on murine IgE responses
Greenfield et al. Toxin conjugates.
PT82373A (en) Process for preparing a klebsiella capsular polysaccharide vaccine
TH5452EX (th) วัคซีนสังเคราะห์เพื่อต่อต้านฟันผุ
FR2685333B1 (fr) Nouveau peptide notamment pour la realisation de conjugues immunogenes anti-lhrh, vaccins les incorporant et ensemble de vaccination y relatif.